Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 132.29 Million EUR | -13.94% |
| 2022 | 153.71 Million EUR | -3.96% |
| 2021 | 160.05 Million EUR | 5.68% |
| 2020 | 151.44 Million EUR | -17.67% |
| 2019 | 183.94 Million EUR | -35.23% |
| 2018 | 283.97 Million EUR | 67.97% |
| 2017 | 169.06 Million EUR | -13.48% |
| 2016 | 195.4 Million EUR | -16.45% |
| 2015 | 233.88 Million EUR | 1355.98% |
| 2014 | 16.06 Million EUR | 3.0% |
| 2013 | 15.59 Million EUR | -37.44% |
| 2012 | 24.93 Million EUR | -25.54% |
| 2011 | 33.48 Million EUR | 131.02% |
| 2010 | 14.49 Million EUR | -15.22% |
| 2009 | 17.09 Million EUR | -12.42% |
| 2008 | 19.52 Million EUR | 44.1% |
| 2007 | 13.54 Million EUR | 5.13% |
| 2006 | 12.88 Million EUR | 174.05% |
| 2005 | 4.7 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 122.7 Million EUR | 0.0% |
| 2024 Q1 | 122.7 Million EUR | -7.25% |
| 2023 Q1 | 141.18 Million EUR | -8.15% |
| 2023 Q2 | 141.18 Million EUR | 0.0% |
| 2023 Q4 | 132.29 Million EUR | 0.0% |
| 2023 Q3 | 132.29 Million EUR | -6.3% |
| 2023 FY | 132.29 Million EUR | -13.94% |
| 2022 Q2 | 164.09 Million EUR | 0.0% |
| 2022 Q1 | 164.09 Million EUR | 2.52% |
| 2022 FY | 153.71 Million EUR | -3.96% |
| 2022 Q3 | 153.71 Million EUR | -6.33% |
| 2022 Q4 | 153.71 Million EUR | 0.0% |
| 2021 Q3 | 160.05 Million EUR | 20.65% |
| 2021 FY | 160.05 Million EUR | 5.68% |
| 2021 Q4 | 160.05 Million EUR | 0.0% |
| 2021 Q2 | 132.65 Million EUR | 0.0% |
| 2021 Q1 | 132.65 Million EUR | -12.41% |
| 2020 Q2 | 125.3 Million EUR | 0.0% |
| 2020 Q4 | 151.44 Million EUR | 0.0% |
| 2020 FY | 151.44 Million EUR | -17.67% |
| 2020 Q1 | 125.3 Million EUR | -31.88% |
| 2020 Q3 | 151.44 Million EUR | 20.87% |
| 2019 Q4 | 183.94 Million EUR | 0.0% |
| 2019 FY | 183.94 Million EUR | -35.23% |
| 2019 Q1 | 171.28 Million EUR | -39.68% |
| 2019 Q2 | 171.28 Million EUR | 0.0% |
| 2019 Q3 | 183.94 Million EUR | 7.39% |
| 2018 FY | 283.97 Million EUR | 67.97% |
| 2018 Q4 | 283.97 Million EUR | 0.0% |
| 2018 Q3 | 283.97 Million EUR | 104.67% |
| 2018 Q2 | 138.74 Million EUR | 0.0% |
| 2018 Q1 | 138.74 Million EUR | -17.93% |
| 2017 FY | 169.06 Million EUR | -13.48% |
| 2017 Q4 | 169.06 Million EUR | 0.0% |
| 2017 Q3 | 169.06 Million EUR | -4.74% |
| 2017 Q2 | 177.47 Million EUR | 0.0% |
| 2017 Q1 | 177.47 Million EUR | -9.18% |
| 2016 Q3 | 195.4 Million EUR | -8.32% |
| 2016 FY | 195.4 Million EUR | -16.45% |
| 2016 Q4 | 195.4 Million EUR | 0.0% |
| 2016 Q2 | 213.15 Million EUR | 0.0% |
| 2016 Q1 | 213.15 Million EUR | -8.87% |
| 2015 Q1 | 235.9 Million EUR | 1368.53% |
| 2015 Q2 | 235.9 Million EUR | 0.0% |
| 2015 Q3 | 233.88 Million EUR | -0.85% |
| 2015 Q4 | 233.88 Million EUR | 0.0% |
| 2015 FY | 233.88 Million EUR | 1355.98% |
| 2014 Q2 | 18.44 Million EUR | 0.0% |
| 2014 Q3 | 16.06 Million EUR | -12.92% |
| 2014 Q4 | 16.06 Million EUR | 0.0% |
| 2014 FY | 16.06 Million EUR | 3.0% |
| 2014 Q1 | 18.44 Million EUR | 18.28% |
| 2013 Q2 | 20.33 Million EUR | 0.0% |
| 2013 FY | 15.59 Million EUR | -37.44% |
| 2013 Q4 | 15.59 Million EUR | 0.0% |
| 2013 Q3 | 15.59 Million EUR | -23.32% |
| 2013 Q1 | 20.33 Million EUR | -18.42% |
| 2012 Q4 | 24.93 Million EUR | 0.0% |
| 2012 Q2 | 31.16 Million EUR | 0.0% |
| 2012 FY | 24.93 Million EUR | -25.54% |
| 2012 Q3 | 24.93 Million EUR | -20.01% |
| 2011 Q4 | 33.48 Million EUR | 0.0% |
| 2011 Q2 | 13.29 Million EUR | 0.0% |
| 2011 FY | 33.48 Million EUR | 131.02% |
| 2010 Q2 | 14.78 Million EUR | 0.0% |
| 2010 FY | 14.49 Million EUR | -15.22% |
| 2010 Q4 | 14.49 Million EUR | 0.0% |
| 2009 FY | 17.09 Million EUR | -12.42% |
| 2009 Q4 | 17.09 Million EUR | 0.0% |
| 2008 FY | 19.52 Million EUR | 44.1% |
| 2007 FY | 13.54 Million EUR | 5.13% |
| 2006 FY | 12.88 Million EUR | 174.05% |
| 2005 FY | 4.7 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -148.179% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1280.627% |
| SQZ Biotechnologies Company | 50.03 Million USD | -164.378% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -82.545% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -124.17% |
| Mesoblast Limited | 188.44 Million USD | 29.798% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3334.885% |
| Genus plc | 485 Million USD | 72.723% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2164.258% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -5157.343% |
| Marizyme, Inc. | 26.67 Million USD | -395.927% |
| ContraFect Corporation | 32.53 Million USD | -306.664% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3381.368% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6577.003% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3356.222% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1001.629% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1023.194% |
| MultiCell Technologies, Inc. | 1617.67 USD | -8177834.931% |
| Accustem Sciences Inc. | 1.07 Million USD | -12157.897% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -70.882% |
| EV Biologics, Inc. | 2.11 Million USD | -6154.737% |
| Q BioMed Inc. | 8.13 Million USD | -1526.62% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -59.513% |
| Neon Bloom, Inc. | 1.22 Million USD | -10688.664% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2470.756% |
| Biomind Labs Inc. | 1.49 Million USD | -8727.635% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 45.798% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -618.845% |
| Skye Bioscience, Inc. | 14.07 Million USD | -840.093% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -6481.266% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -93001.094% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1297.561% |
| IMV Inc. | 37.93 Million USD | -248.754% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -65678.953% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2202.404% |
| GB Sciences, Inc. | 5.41 Million USD | -2341.912% |
| Alpha Cognition Inc. | 7.16 Million USD | -1746.423% |
| HST Global, Inc. | 593.59 Thousand USD | -22186.651% |
| CSL Limited | 18.62 Billion USD | 99.29% |
| Halberd Corporation | 728.71 Thousand USD | -18054.048% |
| Enzolytics Inc. | 365.26 Million USD | 63.782% |
| Resverlogix Corp. | 67.39 Million USD | -96.291% |
| Affymax, Inc. | 8.87 Million USD | -1391.286% |
| SYBLEU INC | 681.41 Thousand USD | -19314.364% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -15672.857% |
| argenx SE | 444.95 Million USD | 70.268% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -76.578% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -7618.32% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1011.408% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3509.443% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3212.48% |
| Zenith Capital Corp. | 27.56 Thousand USD | -479757.811% |
| Genscript Biotech Corporation | 1.32 Billion USD | 90.022% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -55332.551% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3442.613% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -19330.874% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -11.43% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1363.052% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -197560.207% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -9126.278% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -163.194% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -4778.669% |
| BioStem Technologies, Inc. | 15.9 Million USD | -731.781% |
| ONE Bio Corp. | 27.49 Million USD | -381.135% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -28368.32% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -482136.722% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -10406.094% |
| Agentix Corp. | 2.51 Million USD | -5169.432% |
| LadRx Corporation | 2.2 Million USD | -5911.83% |
| Cell Source, Inc. | 15.8 Million USD | -736.935% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -295881.743% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2323.989% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2323.989% |
| NovAccess Global Inc. | 7.86 Million USD | -1582.948% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -434.599% |
| Itoco Inc. | 1.65 Million USD | -7902.415% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -6348.346% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2087.006% |
| Kadimastem Ltd | 3.5 Million USD | -3674.523% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -31280.94% |
| CytoDyn Inc. | 127.89 Million USD | -3.439% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -316395.61% |
| Mobile Lads Corp. | 1.31 Million USD | -9971.74% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -8345.732% |
| Qrons Inc. | 1.48 Million USD | -8786.333% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1097.723% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -16256.699% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2423.693% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2068.044% |
| International Stem Cell Corporation | 5.27 Million USD | -2406.955% |
| Bioxytran, Inc. | 3.24 Million USD | -3971.149% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -21039.357% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2765.246% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -222.695% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -494.17% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -6431.69% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2314.969% |
| Neutra Corp. | 973.52 Thousand USD | -13488.912% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -355.943% |
| PureTech Health plc | 125.58 Million USD | -5.342% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3421.097% |
| IXICO plc | 1.9 Million USD | -6861.667% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -544.415% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -28.036% |
| CSL Limited | 18.62 Billion USD | 99.29% |
| Cellectis S.A. | 249.36 Million USD | 46.949% |